British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

GSK plc (LSE/NYSE: GSK) announced its sponsorship of the 2025 National Senior Games as part of its nationwide Sideline RSV campaign, a health education campaign aimed at helping educate older adults ...

GSK PLC a annoncé jeudi que la version en seringue préremplie de son vaccin Shingrix a été approuvée aux États-Unis pour la prévention du zona. Le laboratoire pharmaceutique basé à Londres ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend the indication of Arexvy (respiratory syncytial virus (RSV) ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.

In the US, AREXVY is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older. GSK’s RSV older adult vaccine is not currently approved anywhere outside the US.

The application is supported by positive results from a phase III trial [NCT05590403] 4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including ...

Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk (CNW Group/GlaxoSmithKline Inc.) ...

GSK plc has announced its sponsorship of the 2025 National Senior Games as part of its Sideline RSV campaign, a nationwide health education initiative aimed at informing adults ...

Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time The approval is based on data from the positive pivotal AReSVi-006 phase III trial ...

The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. About respiratory syncytial virus (RSV) ...